Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28875175 | 0.89 | TDP1 (0.68) | LMNATDP1MAPK1HIF1ASLC6A2 | |
| SCHEMBL51601 | 0.89 | TDP1 (0.68) | LMNATDP1MAPK1HIF1ASLC6A2 | |
| SCHEMBL3958327 | 0.84 | LMNA (0.69) | LMNATDP1MAPK1HIF1ASLC6A2 | |
| SCHEMBL16020464 | 0.84 | ALDH1A1 (0.50) | LMNATDP1MAPK1SLC6A2KMT2A | |
| SCHEMBL11723334 | 0.84 | LMNA (0.59) | LMNATDP1MAPK1HIF1ASLC6A2 | |
| Ethylene Glycol SCHEMBL15661698 | 0.83 | ALDH1A1 (0.62) | LMNATDP1MAPK1HIF1ASLC6A2 | |
| SCHEMBL11731263 | 0.83 | LMNA (0.57) | LMNATDP1MAPK1HIF1ASLC6A2 | |
| Ethyl Benzoate SCHEMBL27407882 | 0.82 | LMNA (0.61) | LMNATDP1MAPK1HIF1ASLC6A2 | |
| SCHEMBL9768509 | 0.82 | ESR1 (0.63) | LMNATDP1MAPK1SLC6A2KMT2A | |
| SCHEMBL16627110 | 0.82 | TDP1 (0.53) | LMNATDP1KMT2AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119912337-A | Methyl cyclopropene benzoic acid probe and preparation method and application thereof | 贵州医科大学 | 2025-05-02 | — | — | CN | disclosed |
| CN-119264128-A | Thiadiazole and pyridazine parent nucleus compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2025-01-07 | — | — | CN | disclosed |
| EP-3906969-A1 | ANTIHYPERTENSIVE POLYOL COMPOUND AND DERIVATIVE THEREOF | East China University of Science and Technology (CN) | 2021-11-10 | — | — | EP | disclosed |
| WO-2020249117-A1 | ANTIHYPERTENSIVE POLYOL COMPOUND AND DERIVATIVE THEREOF | 华东理工大学 | 2020-12-17 | — | — | WO | disclosed |
| US-20190382422-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-12-19 | — | — | US | disclosed |
| US-10377780-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-08-13 | — | — | US | disclosed |
| US-20170267704-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-09-21 | — | — | US | disclosed |
| US-9650399-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-05-16 | — | — | US | disclosed |
| US-20160361315-A1 | IBRUTINIB PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | NGUYEN MARK QUANG (US) | 2016-12-15 | — | — | US | disclosed |
| US-9394312-B1 | Ibrutinib prodrugs, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2016-07-19 | — | — | US | disclosed |
| US-20070112040-A1 | Amino nicotinate derivatives as glucokinase (GLK) modulators | ASTRAZENECA AB | 2007-05-17 | — | — | US | disclosed |
| US-20040214868-A1 | Amino nicotinate derivatives as glucokinase (GLK) modulators | ASTRAZENECA AB (SE) | 2004-10-28 | — | — | US | disclosed |
| CN-1520296-A | Amino nicotinate derivatives as glucokinase (GLK) modulators | — | 2004-08-11 | — | — | CN | disclosed |
| EP-1404335-A1 | AMINO NICOTINATE DERIVATIVES AS GLUCOKINASE (GLK) MODULATORS | Astrazeneca AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| EP-1043304-B1 | Method for producing (hydroxyalkyl)alicyclic carboxylic acids and intermediates therefor | NIPPON CATALYTIC CHEM IND (JP) | 2004-02-25 | — | — | EP | disclosed |
| US-6600080-B1 | Method of alcohols such as cyclohexanedimethanol, a benzyl ester is obtained, for example, by the reaction between a benzyl compound and carboxylic acid in the presence of oxygen and a catalyst including palladium, gold ultra fine particles | NIPPON SHOKUBAI CO., LTD. (JP) | 2003-07-29 | — | — | US | disclosed |
| WO-2003000267-A1 | AMINO NICOTINATE DERIVATIVES AS GLUCOKINASE (GLK) MODULATORS | ASTRAZENECA AB (SE) | 2003-01-03 | — | — | WO | disclosed |
| US-6444843-B1 | CATALYTIC OXIDATION | NIPPON SHOKUBAI CO., LTD. (JP) | 2002-09-03 | — | — | US | disclosed |
| EP-1090902-A2 | Method for producing alcohols such as cyclohexanedimethanol | Nippon Shokubai Co., Ltd. (JP) | 2001-04-11 | — | — | EP | disclosed |
| EP-1043304-A1 | Method for producing (hydroxyalkyl)alicyclic carboxylic acids and intermediates therefor | Nippon Shokubai Co., Ltd. (JP) | 2000-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190382422-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | STAT3, STAT5A, STAT6 | LMNA 4606/4885TDP1 2922/4885MAPK1 740/4885 |
| US-20070112040-A1 | Amino nicotinate derivatives as glucokinase (GLK) modulators | GCK, GCKR, NADK | LMNA 2707/4885TDP1 2700/4885MAPK1 626/4885 |
| US-20170267704-A1 | SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF | STAT3, STAT5A, STAT6 | LMNA 4606/4885TDP1 2922/4885MAPK1 740/4885 |
| US-10377780-B2 | Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof | STAT3, STAT5A, STAT6 | LMNA 4606/4885TDP1 2922/4885MAPK1 740/4885 |
| US-20040214868-A1 | Amino nicotinate derivatives as glucokinase (GLK) modulators | GCK, GCKR, NADK | LMNA 2159/4885TDP1 1731/4885MAPK1 277/4885 |
| US-20160361315-A1 | IBRUTINIB PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | BTK, SYK, BCL9 | LMNA 2744/4885TDP1 838/4885MAPK1 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.